Biotechnology
Synergy Therapeutics, a small start-up out of Saint Joseph’s University/Philadelphia College of Pharmacy, is developing ch-p53HSA, the first in class dual agonist/antagonist cholestosome formulated peptide for use in synergistic combination with Kinase Inhibitors.